搜索
 > 【ErbB4】重组蛋白信息

ErbB4信息

英文名称:Receptor protein-tyrosine kinase erbB-4
中文名称:受体蛋白酪氨酸激酶 erbB-4
靶点别称:Proto-oncogene-like protein c-ErbB-4,E4ICD,ERBB4 intracellular domain,Receptor tyrosine-protein kinase erbB-4,p180erbB4,HER4,s80HER4,Tyrosine kinase-type cell surface receptor HER4,ERBB4,4ICD
上市药物数量:4
临床药物数量:11
最高研发阶段:批准上市

ErbB4产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
ER4-H5221
Human
Human ErbB4 / Her4 Protein, His Tag
ER4-H5251
Human
Human ErbB4 HER4 Protein, With C-Fc Tag

ErbB4 分子别名

HER4,ErbB4,MGC138404,p180erbB4

ErbB4 分子背景

Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4, NRG1, STAT5A, and YAP1. Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.

ErbB4 参考文献

ErbB4上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Afatinib Dimaleate 马来酸阿法替尼 BIBW-2992; BIBW-2992-MA2,BIBW 2992,BIBW2992 批准上市 勃林格殷格翰 GILOTRIF fda 转移性鳞状细胞非小细胞肺癌, 非小细胞肺癌 BOEHRINGER INGELHEIM 2013-07-12 转移性鳞状细胞非小细胞肺癌, 非小细胞肺癌 详情
Neratinib Maleate 马来酸来那替尼 CAN-030; HKI-272; PB-272; PF-0528767; WAY-179272 批准上市 辉瑞, Puma Biotechnology, 北海康成 NERLYNX fda HER2阳性转移性乳腺癌 PUMA BIOTECH 2017-07-17 HER2阳性转移性乳腺癌 详情
Dacomitinib 达可替尼 PF-00299804; PF-299; PF-299804; PF-804; PF-00299804-03; PF-00299804-3,PF00299804,PF299804,PF299 批准上市 辉瑞, SFJ pharmaceuticals VIZIMPRO fda 非小细胞肺癌 PFIZER INC 2018-09-27 非小细胞肺癌 详情
Pyrotinib Maleate 马来酸吡咯替尼 SHR-1258; BLTN; HTI-1001 批准上市 江苏恒瑞 Pyrotinib Maleate Tablets cfda HER2阳性转移性乳腺癌 2018-08-12 HER2阳性转移性乳腺癌 详情

ErbB4临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Pirotinib Hydrochloride KBP-5209,KBP5209 临床二期 轩竹医药 非小细胞肺癌, 乳腺癌, 肺癌 详情
Allitinib Tosylate AST-6; ALS-1306; AST-1306 临床二期 上海艾力斯 乳腺癌, 肺癌
AC-480 AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 临床一期 Ambit biosciences 神经胶质瘤, 实体瘤 详情
Recombinant human neuregulin-1 rhNRG-1 BLA 申请 上海泽生科技, 赛生药业 慢性心力衰竭 详情
Larotinib Mesylate Z-650 临床二期 广东东阳光药 食道癌 详情
BMS-690514 BMS-690514,BMS690514 临床二期 百时美施贵宝 非小细胞肺癌, 乳腺癌 详情
Tesevatinib EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 临床三期 Exelixis, Kadmon 非小细胞肺癌, 常染色体显性多囊肾病 详情
PB-357 PB-357 临床一期 辉瑞 实体瘤
Sirotinib Maleate XZP-5491,XZP5491 临床一期 轩竹医药 食管鳞癌, 非小细胞肺癌, 胃癌
Tarloxotinib Bromide TH-4000; PR-610; SN-33999 临床二期 Threshold 非小细胞肺癌 详情
Poziotinib HM-78136; HM-78136B; NOV1201; NOV-120101 临床二期 韩美, 绿叶制药, Spectrum Pharmaceuticals 非小细胞肺癌, 胃癌, 乳腺癌, 头颈癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定